Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M
Executive Summary
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
You may also be interested in...
Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
PacBio Agrees To Pay $800M For Omniome To Add Complementary Short-Read Sequencing Platform
Pacific Biosciences has agreed to pay $600m upfront in cash and stock and up $200m in additional milestone payments to acquire Omniome. PacBio also announced a new private placement of common stock to raise $300m.
Big Money Spent On Liquid Biopsy Technology In 2021
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.